Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Craig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU)

Tipranks - Tipranks - Wed May 21, 2025

In a report released today, Albert Lowe from Craig-Hallum maintained a Buy rating on Actuate Therapeutics, Inc. (ACTU – Research Report). The company’s shares closed yesterday at $10.26.

Confident Investing Starts Here:

According to TipRanks, Lowe is an analyst with an average return of -22.2% and a 24.14% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Actuate Therapeutics, Inc., Lineage Therap, and Opus Genetics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Actuate Therapeutics, Inc. with a $20.50 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $11.73 and a one-year low of $5.51. Currently, Actuate Therapeutics, Inc. has an average volume of 46.64K.

Read More on ACTU:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).